Absci (ABSI) to Release Earnings on Tuesday

Absci (NASDAQ:ABSI) is anticipated to announce its Q2 2025 earnings results after the market closes on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $1.39 million for the quarter.

Absci (NASDAQ:ABSI) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. The firm had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.07 million. Absci had a negative net margin of 2,232.13% and a negative return on equity of 53.69%. On average, analysts expect Absci to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Absci Trading Down 2.7%

Shares of ABSI stock opened at $2.84 on Monday. The business’s 50 day moving average is $2.87 and its two-hundred day moving average is $3.18. Absci has a 12-month low of $2.01 and a 12-month high of $6.33. The company has a market capitalization of $362.27 million, a P/E ratio of -3.09 and a beta of 2.02.

Insider Buying and Selling

In other Absci news, insider Andreas Busch purchased 50,000 shares of the firm’s stock in a transaction that occurred on Monday, July 28th. The stock was purchased at an average price of $3.04 per share, for a total transaction of $152,000.00. Following the purchase, the insider directly owned 327,264 shares in the company, valued at approximately $994,882.56. This trade represents a 18.03% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 10.49% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Absci

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Creative Planning raised its position in Absci by 145.4% during the 2nd quarter. Creative Planning now owns 46,882 shares of the company’s stock worth $120,000 after buying an additional 27,775 shares during the last quarter. AQR Capital Management LLC raised its holdings in Absci by 279.4% during the first quarter. AQR Capital Management LLC now owns 55,538 shares of the company’s stock worth $139,000 after purchasing an additional 40,901 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Absci by 17.5% during the first quarter. Goldman Sachs Group Inc. now owns 314,858 shares of the company’s stock worth $790,000 after purchasing an additional 46,975 shares in the last quarter. Woodline Partners LP lifted its position in Absci by 32.9% in the first quarter. Woodline Partners LP now owns 1,391,245 shares of the company’s stock valued at $3,492,000 after purchasing an additional 344,270 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Absci by 22.5% in the 2nd quarter. Geode Capital Management LLC now owns 2,445,450 shares of the company’s stock valued at $6,286,000 after purchasing an additional 448,984 shares in the last quarter. 52.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ABSI has been the subject of several research analyst reports. KeyCorp upped their price target on shares of Absci from $5.00 to $9.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 16th. Morgan Stanley lowered their target price on shares of Absci from $7.00 to $6.40 and set an “overweight” rating for the company in a research note on Monday, July 28th. Wall Street Zen upgraded shares of Absci from a “sell” rating to a “hold” rating in a report on Saturday, August 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $9.00 price target on shares of Absci in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $8.28.

Absci Company Profile

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.